JP Patent

JP2013543845A — Ｃｄｋ阻害剤

Assigned to G1 Therapeutics Inc · Expires 2013-12-09 · 12y expired

What this patent protects

式Ｉ、ＩＩ、又はＩＩＩの化合物及びその薬学的に許容される塩はＣＤＫ阻害剤として有用である。

USPTO Abstract

式Ｉ、ＩＩ、又はＩＩＩの化合物及びその薬学的に許容される塩はＣＤＫ阻害剤として有用である。

Drugs covered by this patent

trilaciclib-dihydrochloride (TRILACICLIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: JP2013543845A
Jurisdiction: JP
Classification: —
Expires: 2013-12-09
Drug substance claim: No
Drug product claim: No
Assignee: G1 Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.